J
James A. Bonner
Researcher at University of Alabama at Birmingham
Publications - 252
Citations - 17463
James A. Bonner is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Radiation therapy & Cetuximab. The author has an hindex of 56, co-authored 237 publications receiving 16175 citations. Previous affiliations of James A. Bonner include University of Alabama & University of Michigan.
Papers
More filters
Journal Article
Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers
James A. Bonner,Kevin P. Raisch,Hoa Q. Trummell,Francisco Robert,Ruby F. Meredith,Sharon A. Spencer,Donald J. Buchsbaum,Mansoor N. Saleh,Murray A. Stackhouse,Albert F. LoBuglio,Glenn E. Peters,William R. Carroll,Harlan W. Waksal +12 more
TL;DR: Preclinical work serves as important support for the ongoing clinical investigation of C225 and radiotherapy for patients with head and neck carcinomas by indirectly linking C225/radiation-induced regulation of STAT-3 protein to apoptosis.
Journal ArticleDOI
Quality of Life in Head and Neck Cancer Patients After Treatment With High-Dose Radiotherapy Alone or in Combination With Cetuximab
Desmond Curran,Jordi Giralt,Paul M. Harari,K. Kian Ang,Roger B. Cohen,Merrill S. Kies,Jacek Jassem,José Baselga,Eric K. Rowinsky,Nadia Amellal,Sylvie Comte,James A. Bonner +11 more
TL;DR: The addition of cetuximab to radiotherapy significantly improved locoregional control and increased overall survival without adversely affecting QoL.
Journal ArticleDOI
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.
Audrey Mauguen,Cécile Le Péchoux,Michele I. Saunders,Steven E. Schild,Andrew T. Turrisi,Michael Baumann,William T. Sause,David Ball,Chandra P. Belani,James A. Bonner,A. Zajusz,Suzanne E. Dahlberg,Matthew Nankivell,Sumithra J. Mandrekar,Rebecca Paulus,Katarzyna Behrendt,Rainer Koch,James F. Bishop,Stanley Dische,Rodrigo Arriagada,Rodrigo Arriagada,Dirk De Ruysscher,Jean Pierre Pignon +22 more
TL;DR: Patients with nonmetastatic NSCLC derived a significant OS benefit from accelerated or hyperfractionated radiotherapy; a similar but nonsignificant trend was observed for SCLC; as expected, there was increased acute esophageal toxicity.
Journal ArticleDOI
The Outcome of Combined-Modality Therapy for Stage III Non-Small-Cell Lung Cancer in the Elderly
Steven E. Schild,Philip J. Stella,Susan Geyer,James A. Bonner,William L. McGinnis,James A. Mailliard,Jeffery Brindle,Aminah Jatoi,James R. Jett +8 more
TL;DR: Toxicity, especially myelosuppression and pneumonitis, was more pronounced in the elderly patients receiving combined-modality therapy for locally advanced NSCLC, and fit, elderly patients with locally advancedNSCLC should be encouraged to receive combined- modality therapy, preferably on clinical trials with cautious, judicious monitoring.
Journal ArticleDOI
Biology of Interactions: Antiepidermal Growth Factor Receptor Agents
TL;DR: Through improved understanding of EGFR biology in human cancers, there is anticipation that more tumor-selective therapy approaches with diminished collateral normal tissue toxicity can be advanced, and many questions remain to be answered.